Skip to main content

Table 2 Factor correlation with PHQ-9 changes

From: Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

 

Univariable

Multivariable

PHQ-9 mean difference (95% CI)

p-value

PHQ-9 mean difference (95% CI)

p-value

Age

− 0.05 (− 0.01 to 0.008)

0.096

 

NS

Sex (male)

0.64 (− 1.4 to 2.70)

0.537

  

CD4, every 100 cells/μl

− 0.03 (− 0.2 to 0.2)

0.713

  

Viral suppression

− 3.4 (− 5.7 to − 1.2)

0.003

− 3.2 (− 0.9 to − 5.4)

0.006

PHQ-9 ≥ 10 before DTG

− 2.8 (− 4.3 to − 1.3)

< 0.001

− 2.7 (− 1.2 to − 4.2)

< 0.001

PHQ-9 ≥ 15 before DTG

− 6.2 (− 8.6 to − 3.7)

< 0.001

  

EFV use before DTG

0.11 (− 1.1 to 1.3)

0.859

  
  1. PHQ-9 change = PHQ-9 at 2nd assessment minus PHQ-9 at 1st assessment
  2. Statistical method: Linear regression with PHQ-9 change as dependent variable
  3. Factors with p < 0.1 in the univariable model were included into multivariable analysis
  4. NS not significant, PHQ-9 Patient Health Questionnaire-9, EFV Efavirenz
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us